SWOG clinical trial number
SWOG-9438

Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma, A BMT Study, Phase III

Closed
Phase
Accrual
98%
Published
Abbreviated Title
NON-HODGKIN'S: Debulking salvage chemo adn stem cell harvest -> TBI/cyclophosphamide -> PBSCT and randmization to IL-2 or obs.
Activated
05/15/1995
Closed
07/01/2004
Participants
Limited Institutions: BMT Members

Research committees

Lymphoma

Treatment

Cyclophosphamide Allopurinol Interleukin-2 Trimethoprim sulfa VP-16 Radiation Therapy

Eligibility Criteria Expand/Collapse

Biopsy proven low, intermediate or high grade NHL (D-H & J); relapsed following CR or PR or no response to prior therapy (as listed in protocol); age 16-60; HIV neg; no prior BMT; no CNS involvement; no hist. of seizures; no heart problems; no allergy to VP-16; no prior IL-2; no prior involved field RT; no autoimmune
disease or prior allogeneic organ transplant.

Publication Information Expand/Collapse

2013

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

2008

Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: Results of a Phase III randomized trial by the Southwest Oncology Group (SWOG 9438) [PMC2288718; PMID18256325]

JA Thompson;RI Fisher;M LeBlanc;SJ Forman;OW Press;JM Unger;AP Nademanee;PJ Stiff;SH Petersdorf;A Fefer Blood 111(8):4048-4054

2004

Impact of increased body weight on acute toxicity and outcome of autologous stem cell transplantation for non-Hodgkin's lymphoma: a Southwest Oncology Group analysis

P Stiff;J Unger;S Forman;M LeBlanc;T Miller;O Press;J Thompson;R Fisher Blood 104(11): #352

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
12%
Open
Phase